Anti-CD20 Bispecifics Could Find Niche In First-Line Lymphoma
Highly Entrenched Rituxan Could Prove Tough To Dislodge
Roche presented data at ASCO on its two CD20-targeting bispecific antibodies, showing high response rates in heavily pretreated non-Hodgkin lymphoma patients.
You may also be interested in...
Novartis hopes a CAR-T with rapid manufacturing will be a winner, while novel bispecific antibodies in lymphoma and myeloma will make appearances, along with next-generation PI3K and BTK inhibitors.
The company created two new divisions focused on the new disease areas, bringing in former executives from Bristol Myers Squibb and Sanofi Pasteur.
Despite legacy cancer drug sales still being hurt by biosimilars, Roche at the half-year mark is expected to give another good overall performance and underscore its growing product diversity and an increasing interest in rare diseases.